had told me a decision could be made by the end of this week regarding the Dendreon saga.
You may recall that at least three Congressmen have asked the committee to hold a hearing on alleged conflicts of interest and ethical violations among two of the Food and Drug Administration Advisory Committee members who reviewed Dendreon's prostate cancer drug Provenge last year.
The spokesperson said the committee Chair, Rep. John Dingell (D-MI), and his subcommittee chairs would be meeting this week to start setting their agenda for this year.
Since I know there are many Dendreonians who are anxiously awaiting a go/no-go decision from the committee, I just wanted to blog before the weekend that I'm on it and that the same spokesperson has just informed me that no decision has been made yet.
Questions? Comments? Pharma@cnbc.com